A melanoma specimen is being tested because systemic treatment may be required. BRAF V600E immunohistochemistry is negative, but morphology and

Question

A melanoma specimen is being tested because systemic treatment may be required. BRAF V600E immunohistochemistry is negative, but morphology and clinical context leave a targetable BRAF alteration possible. What does NICE advise next?

Accepted Answer

Use a different BRAF genetic assay after negative V600E immunohistochemistry

Answer

Request germline BRAF analysis because an actionable tumour alteration is likely to be inherited

Answer

Use tumour PD-L1 immunohistochemistry as the next surrogate test for BRAF pathway activation

Answer

Repeat V600E immunohistochemistry on serial sections before requesting a genetic assay

Answer

Report BRAF wild type because negative V600E immunohistochemistry completes molecular testing

Cervical Cancer Surveillance — SCE Medical Oncology MCQ

A melanoma specimen is being tested because systemic treatment may be required. BRAF V600E immunohistochemistry is negative, but morphology and clinical context leave a targetable BRAF alteration possible. What does NICE advise next?